1. Home
  2. GIB vs NBIX Comparison

GIB vs NBIX Comparison

Compare GIB & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CGI Inc.

GIB

CGI Inc.

HOLD

Current Price

$62.19

Market Cap

12.8B

ML Signal

HOLD

Logo Neurocrine Biosciences Inc.

NBIX

Neurocrine Biosciences Inc.

HOLD

Current Price

$164.01

Market Cap

13.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GIB
NBIX
Founded
1976
1992
Country
Canada
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.8B
13.2B
IPO Year
1999
1996

Fundamental Metrics

Financial Performance
Metric
GIB
NBIX
Price
$62.19
$164.01
Analyst Decision
Hold
Strong Buy
Analyst Count
3
22
Target Price
$112.00
$180.91
AVG Volume (30 Days)
418.6K
1.1M
Earning Date
04-29-2026
05-05-2026
Dividend Yield
0.70%
N/A
EPS Growth
N/A
41.95
EPS
N/A
1.91
Revenue
N/A
$161,626,000.00
Revenue This Year
$8.33
$24.73
Revenue Next Year
$2.96
$13.14
P/E Ratio
$13.59
$87.09
Revenue Growth
N/A
977.51
52 Week Low
$59.63
$122.14
52 Week High
$106.68
$169.57

Technical Indicators

Market Signals
Indicator
GIB
NBIX
Relative Strength Index (RSI) 37.64 58.86
Support Level $61.35 $153.96
Resistance Level $70.68 $169.57
Average True Range (ATR) 1.95 4.68
MACD -0.42 -0.44
Stochastic Oscillator 29.02 61.36

Price Performance

Historical Comparison
GIB
NBIX

About GIB CGI Inc.

CGI is a Canada-based IT-services provider with an embedded position in North America and Europe. The company is one of the major IT suppliers to different levels of government around the world. It offers a broad portfolio of services such as consulting, systems integration, application maintenance, and business process services to governments and the private sector. With offices in over 40 countries, CGI follows a balanced global delivery model with most consultants in client proximity.

About NBIX Neurocrine Biosciences Inc.

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

Share on Social Networks: